There are 412 resources available
218P - Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib (palbo) in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Updated phase Ib cohort results
Presenter: Erika Hamilton
Session: Lunch and Poster Display session
219P - New prognostic factors in advanced HR+ HER2- breast cancer treated with CDK4/6 inhibitors
Presenter: Sonia Crocetti
Session: Lunch and Poster Display session
220P - Impact of time to progression (TTP) on CDK4/6 inhibitor (CDK4/6i) therapy on progression-free survival (PFS) in HR+/HER2-/PIK3CA-mutated advanced breast cancer (aBC) patients (pts) treated with alpelisib plus endocrine therapy (ALP+ET): An exploratory analysis of the METALLICA trial
Presenter: Juan José García-Mosquera
Session: Lunch and Poster Display session
221P - Incidence and survival after brain metastases among patients with stage I-III breast cancer: A population-based study
Presenter: Italo Fernandes
Session: Lunch and Poster Display session
222P - Poor response to cyclin dependent kinase 4/6 inhibition in metastatic inflammatory breast cancer
Presenter: Azadeh Nasrazadani
Session: Lunch and Poster Display session
223P - Real-world treatment efficacy of ribociclib or palbociclib plus fulvestrant in hormone receptor-positive/HER2-negative metastatic breast cancer: Turkish Oncology Group (TOG) study
Presenter: Seda Kahraman
Session: Lunch and Poster Display session
224P - Efficacy of single-agent second-line fulvestrant (FUL) in metastatic invasive lobular carcinoma (mILC) exposed to first-line aromatase inhibitors (AI) and cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is)
Presenter: Jason Mouabbi
Session: Lunch and Poster Display session
225P - Impact of cyclin inhibitors (CDK4/6i) on immune cell populations in first-line treated metastatic breast cancer (mBC) patients
Presenter: María Luisa Sánchez-León
Session: Lunch and Poster Display session
226P - Prevalence and characteristics of HR+/HER2- MBC with ESR1 mutations post-CDK inhibitor therapy
Presenter: Antonio Marra
Session: Lunch and Poster Display session
227P - The role of CDK4/6 inhibitors in sequencing of endocrine treatment in metastatic breast cancer or can we accept the SONIA trial results in real-world practice?
Presenter: Olesya Stativko
Session: Lunch and Poster Display session